CTICasesInfliximab-Induced Lymphoplasmacytic Infiltrate
[...]. Infliximab-Induced Lymphoplasmacytic Infiltrate. CTICases. Published August 13, 2021. https://str-case-explorer.pages.dev/c/hw2fv
Imaging findings
Chest radiographs and CT demonstrate widespread, bilateral, ground-glass opacities and areas of consolidation predominantly involving the lung bases. A subsequent biopsy demonstrates a benign, polyclonal lymphoplasmacytic infiltrate without malignant features, which completely cleared following drug cessation and a course of corticosteroid therapy.
Key takeaways
Anti-TNF agents such as infliximab can occasionally trigger a drug-induced pulmonary reaction characterized by a polyclonal lymphoplasmacytic infiltrate. This must be distinguished from malignant lymphoproliferative disorders or progressive infections, as management relies on withdrawing the offending biologic agent and administering systemic corticosteroids.
AI-assisted summary — may contain errors. Verify against the source video. Learn more
More from this webinar
- Thalassemia with Extramedullary HematopoiesisMetabolic
- Traumatic Aortic TransectionAorta & Arteries
- Pulmonary CoccidioidomycosisInfection
- Surfactant Protein C Mutation-Associated Pulmonary FibrosisILD
- Iatrogenic Aortic Injury from Intra-Aortic Balloon Pump (IABP)Aorta & Arteries
- Spontaneous Coronary Artery Dissection (SCAD)Coronary
- Post-Lobectomy Pulmonary Vein Stump ThrombusVascular
- Pulmonary ActinomycosisInfection
See all cases from August 13, 2021 →
Related Inflammatory cases
- Asian Panbronchiolitis
- Immune Reconstitution Inflammatory Syndrome (IRIS)
- ROR1 CAR T-Cell Therapy-Induced Cytokine Release Syndrome
- Foreign Body Granuloma from BioSentry Biopsy Tract Sealant
- Pancreatitis with Pancreatic Pseudocyst Eroding through the Diaphragm
- Unicentric Hyaline Vascular Castleman Disease